No Data
Xi'an International Medical Investment (000516): Hospitals improve quality and expand revenue, continuous reduction of losses, expecting to turn losses around in 2025.
Performance Summary 24th October 2024, the company released the third quarter report of 2024, with revenue, net profit attributable to shareholders, and non-recurring net income for the first three quarters of 1.04/0.217/0.168 billion yuan respectively, a year-on-year increase of 22.38%.
xi'an international medical investment (000516): Steady income and profitability, continuous optimization of specialist layout.
On October 24th, the company released the 2024 third quarter report: Revenue for the first three quarters of 2024 was 3.606 billion yuan (+7.85%), net income attributable to the parent company was -0.212 billion yuan (+4.59%).
International Medicine: third quarter report 2024
xi'an international medical investment (000516.SZ): a net loss of 0.212 billion yuan in the first three quarters.
On October 24, Gelonhui announced its third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 3.606 billion yuan, a year-on-year increase of 7.85%; net income attributable to shareholders of the listed company was a loss of 0.212 billion yuan, a year-on-year increase of 4.59%; net income after deducting non-recurring gains and losses was a loss of 0.22 billion yuan, a year-on-year increase of 37.20%; basic earnings per share was -0.0954 yuan per share.
Obesity affects employment, eli lilly and co will try to use weight loss drugs to address the issue of unemployment in the united kingdom.
Peking time on the evening of the 15th, usa pharmaceutical giant eli lilly and co signed a major investment agreement with the united kingdom to explore the use of weight-loss drugs to curb unemployment. The weight-loss treatment company and the developer of the Zepbound drug announced on Monday that it will invest 0.279 billion british pounds (approximately 0.364 billion us dollars) to help address a major health challenge in the united kingdom—obesity, of course, being among them. The strategic cooperation between eli lilly and co and the UK Department of Health and Social Care (DHSC) and the Department of Science, Innovation and Technology (DSIT) is the first.
xi'an international medical investment (000516.SZ): cumulative repurchase of 0.4865% of the company's shares
Gelonghui October 8th | xi'an international medical investment (000516.SZ) announced that as of September 30, 2024, the company has repurchased a total of 10,997,100 shares of the company through the Shenzhen Stock Exchange trading system through centralized competitive bidding, accounting for 0.4865% of the company's current total share capital, with a highest fill price of 5.618 yuan/share and a lowest fill price of 4.61 yuan/share. The total amount traded was 57,426,831.72 yuan (excluding transaction fees).
No Data
No Data